Shares of Syneos Health SYNH remained unaffected after the company reported Q4 results.
Quarterly Results
Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.
Revenue of $1,140,000,000 decreased by 6.02% year over year, which were in line with the estimate of $1,140,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $4.09 and $4.38.
The upcoming fiscal year's revenue expected to be between $5,125,000,000 and $5,325,000,000.
How To Listen To The Conference Call
Date: Feb 18, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/h8kqo86z
Recent Stock Performance
Company's 52-week high was at $81.35
Company's 52-week low was at $30.02
Price action over last quarter: Up 47.21%
Company Overview
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.